A diketopiperazine fragment of human serum albumin modulates T-lymphocyte cytokine production through Rap1

Journal of Trauma - Injury, Infection and Critical Care

Volumn 64, Issue 1, 2008, Pages 35-41

  Shimonkevitz, Richard ^a   Thomas, Gregory ^b   Slone, Denetta Sue ^a   Craun, Michael ^a   Mains, Charles ^c   Bar Or, David ^a,b  

^a SWEDISH MEDICAL CENTER   (United States)

^b DMI BioSciences Inc   (United States)

^c St Anthony Central Hospital   (United States)

Author keywords

Anergy; Cytokine; Diketopiperazine; Rap1; T lymphocyte

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ASPARTYLALANYLDIKETOPIPERAZINE; CYTOKINE; GAMMA INTERFERON; GUANOSINE TRIPHOSPHATASE; HUMAN SERUM ALBUMIN; PIPERAZINEDIONE; PROTEIN C JUN; RAP1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME IMMUNOASSAY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTE CULTURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WESTERN BLOTTING;

ACTIVATING TRANSCRIPTION FACTOR 2; BLOTTING, WESTERN; CELL LINE; DIPEPTIDES; GUANOSINE TRIPHOSPHATE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-8; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; RAP GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TELOMERE-BINDING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38149001592     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3181589ff9     Document Type: Article

References (19)

1. Finfer S, Norton R, Bellomo R, Boyce N, French J, Myburgh J. The SAFE study: saline vs. albumin for fluid resusitation in the critically ill. Vox Sang. 2004;87(Suppl 2):123-131.
2. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41:1211-1219.
3. Bar-Or D, Bar-Or R, Rael LT, Gardner D, Slone DS, Craun M. Heterogeneity and oxidation status of commercial albumin preparations for clinical use. Crit Care Med. 2005;33:1638-1641.
4. Bar-Or D, Thomas GW, Bar-Or R, et al. Commercial albumin preparations for clinical use are immunosuppressive in vitro. Crit Care Med. 2006;34:1707-1712.
5. Newell CL, Deisseroth AB, Lopez-Berestein G. Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc Biol. 1994;56:27-35.
6. Nakahira M, Ahn HJ, Park WR, et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol. 2002;168:1146 -1153.
7. Franklin RA, Tordai A, Patel H, Gardner AM, Johnson GL, Gelfand EW. Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. J Clin Invest. 1994;93:2134-2140.
8. Bos JL. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. EMBO J. 1998;17:6776-6782.
9. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science. 1997;124-128.
10. Reedquist KA, Bos JL. Costimulation through CD28 suppresses T cell receptor-dependent activation of the Ras-like small GTPase Rap1 in human T lymphocytes. J Biol Chem. 1998;273:4944-4949.
11. Dillon TJ, Carey KD, Wetzel SA, Parker DC, Stork PJS. Regulation of the small GTPase Rap1 and extracellular signal-regulated kinases by the costimulatory molecule CTLA-4. Mol Cell Biol. 2005;25:4117-4128.
12. Kunsch C, Rosen CA. NF-B subunit-specific regulation of the Interleukin-8 promoter. Mol Cell Biol. 1993;13:6137-6146.
13. Powers KA, Kapus A, Khadaroo RG, et al. Twenty-five percent albumin prevents lung injury following shock/resusitation. Crit Care Med. 2003;31:2355-2363.
14. Cantin AM, Paquette B, Richter M, Larivee P. Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation. Am J Respir Crit Care Med. 2000;162:1539-1546.
15. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med. 2005;33:1681-1687.
16. Osband AJ, Deitch EA, Hauser CJ, et al. Albumin protects against gut-induced lung injury in vitro and in vivo. Ann Surg. 2004;240:331-339.
17. Chen Z-B, Wang Z-W, Ding C-Y, et al. Can albumin administration relieve lung injury in trauma/hemorrhagic shock? World J Gastroenterol. 2006;12:6884-6888.
18. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFα in pulmonary pathophysiology. Respir Res. 2006;7:125-134.
19. Lin WJ, Yeh WC. Implication of toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock. 2005;24:206-209.